Navigation Links
Kiadis Pharma Announces Enrollment of First Patients in a Multinational Registration Study for ATIR(TM)
Date:11/30/2009

AMSTERDAM, November 30 /PRNewswire/ -- Biopharmaceutical company Kiadis Pharma announces today that the first patients have been enrolled in its multinational registration clinical trial with ATIR(TM). The study is designed to show reduction in transplant related mortality (TRM) after one year following an allogeneic stem cell transplantation with a mismatched (haplo-identical) donor in blood cancer patients eligible for an allogeneic stem cell transplantation but without having a matched donor available.

The study is currently open for enrollment in centers in Europe and Canada and is designed to serve as a registration trial for European approval.

"We are very pleased to initiate the registration study following excellent clinical results from the phase I/II study with ATIR(TM)." says Dr. Manja Bouman, CEO of Kiadis Pharma. "ATIR(TM) has shown a low TRM at one year post transplantation and a high overall survival in a patient population with no standard treatment options left. As an orphan product addressing a high unmet need, we aim to take advantage of a fast development path for ATIR(TM)."

"As the pioneer of ATIR(TM) I am very excited about this next major development milestone, a multinational registration study" says Dr. Denis Claude Roy of the University of Montreal. "I am a strong believer that ATIR(TM) will open up a whole new treatment field for a very large patient group which currently has no treatment options left."

About ATIR(TM)

ATIR(TM), a donor lymphocyte preparation depleted of alloreactive T-cells, is under development to reduce transplant related mortality (TRM) following an allogeneic hematopoietic stem cell transplantation (HSCT). ATIR(TM) is designed to provide early immune reconstitution to fight infections and remaining tumor cells (by eliminating the use of prophylactic immune suppressants) while preventing acute severe (Grade III
'/>"/>

SOURCE Kiadis Pharma
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Kiadis Pharma Reports Successful End of Phase II Meeting With FDA for Reviroc
2. Kiadis Pharma Receives Orphan Drug Designation for Rhitol(TM) From the FDA
3. EMEA Grants Kiadis Pharma Lead Product ATIR(TM) Orphan Drug Designation
4. Kiadis Pharma Announces Continued Collaboration With Professor Velardi on its Lead Product ATIR(TM)
5. Kiadis Pharma Appoints Dr. Maarten Egeler, MD PhD as Chief Medical Officer
6. Kiadis Pharma Reports ATIR(TM) Clinical Data, Further Supporting its Potential in Mismatched Bone Marrow Transplantations
7. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
8. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
9. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
10. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
11. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/18/2014)... , July 18, 2014  Neogen Corporation (Nasdaq: ... Snyder , Neogen,s chief operating officer and president, has ... will work as a consultant going forward on special ... Snyder has been in this position since September 2013. ... by James Herbert , who has been Neogen,s ...
(Date:7/18/2014)... That is, most of the atoms in our ... in the outer parts of atoms equals the number ... one or more electrons are plucked away from the ... pull from the nucleus. This enhanced pull, causing ... electrons are less vulnerable to the distractions of their ...
(Date:7/18/2014)... , July 18, 2014  Neurotrope, Inc. (OTCQB: NTRP) ... of Directors appointed Co-Chairmen Charles S. Ramat ... on an interim basis, effective immediately. Messrs. Ramat and ... no longer Chief Executive Officer of Neurotrope Bioscience, Inc., ... and whose employment agreement with Neurotrope Bioscience Inc. terminated ...
(Date:7/18/2014)... Emerging Nuclear Power Countries - Market Forecast, ... , The latest report from GlobalData, Emerging Nuclear Power ... to 2030 covers the emerging nuclear market and the ... on key market players and their global market share. ... across the world has also been estimated. , To ...
Breaking Biology Technology:Highly charged ions 2Highly charged ions 3Highly charged ions 4Neurotrope Board of Directors Appoints Chairmen Ramat and Freiman as Interim Co-CEOs 2Neurotrope Board of Directors Appoints Chairmen Ramat and Freiman as Interim Co-CEOs 3Neurotrope Board of Directors Appoints Chairmen Ramat and Freiman as Interim Co-CEOs 4Emerging Nuclear Power Countries - Market Forecast, Key Companies and Development Analysis, Size, Share, Growth, Trend to 2030 2Emerging Nuclear Power Countries - Market Forecast, Key Companies and Development Analysis, Size, Share, Growth, Trend to 2030 3
... electrical hair that lets them link up in ... Southern California biophysicist and his collaborators. The ... and share energy in part through electrically conducting ... the first measurement of electron transport along biological ...
... Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR ) announced ... product candidate, fidaxomicin, will be presented ... Disease Society of America (IDSA) to be held at ... on October 21-24, 2010. (Logo: ...
... N.J. Physicists at Rutgers University have discovered new ... and inexpensive plastic solar cells for pollution-free electricity production. ... in an upcoming issue of the journal Nature ... of light can travel on the order of a ...
Cached Biology Technology:Microbial hair: It's electric 2Microbial hair: It's electric 3Optimer Pharmaceuticals Announces Presentations at Upcoming IDSA Annual Meeting 2Rutgers discovery paves way for development of efficient, inexpensive plastic solar cells 2
(Date:7/21/2014)... has issued a high health risk warning for Yellowknife ... region due to forest fires. Currently 160 wildfires ... plans for evacuation since these fires are endangering people ... area recently comes with mixed results. The rains ... to start others. , This year the Northern Territories ...
(Date:7/21/2014)... School of Medicine-led study suggests that parents of obese ... consequences of childhood weight gain or the importance of ... healthy weight. , The study is published online in ... Dietetics . , "Parents have a hard time changing ... author Kyung Rhee, MD, and an assistant adjunct professor ...
(Date:7/21/2014)... Aqua satellites detected 154 hotspots in areas across Riau ... fires had increased again following a decline in rainfall. ... was far higher than what had been reported one ... The hotspots were scattered in six regencies and municipalities, ... Smoke and the related haze it creates could potentially ...
Breaking Biology News(10 mins):Parents rank their obese children as 'very healthy' 2
... A newly identified defect in a DNA repair system might ... a key chemotherapy drug, possibly putting them at greater risk ... by St. Jude Children,s Research Hospital scientists. The ... acute lymphoblastic leukemia (ALL) patients who are at higher risk ...
... compound tested by UT Southwestern Medical Center investigators destroys several ... 30 million people in the worldwide pandemic of 1918. ... of a human antiviral protein - could potentially be developed ... that tends to mutate into strains resistant to anti-influenza drugs. ...
... [Brown University] Take your time. Hold your horses. ... arguably equal choices, they need time to deliberate. In ... for Parkinson,s disease, that process sometimes doesn,t kick in, ... happens has led scientists to a detailed explanation of ...
Cached Biology News:Newly identified DNA repair defect linked to increased risk of leukemia relapse 2Newly identified DNA repair defect linked to increased risk of leukemia relapse 3Compound kills highly contagious flu strain by activating antiviral protein 2DBS studies show how brain buys time for tough choices 2DBS studies show how brain buys time for tough choices 3
UGT1A7 (E-15)...
... peptide corresponding to the third cytoplasmic loop ... conjugated to KLH. The immunizing peptide has ... gene. Physical form: Solution in phosphate ... azide. Titertest method: IHC (p). ...
... Human Pathogenic Viruses The National ... preserves well characterised, authenticated human ... facility, and NCPV is able ... nucleic acids derived from them, ...
... easy to use Ascent Software ... members of the Ascent microplate ... clear and easy-to-follow approach with ... and highly sophisticated data handling, ...
Biology Products: